BP素联合PF方案治疗90例中晚期恶性肿瘤患者的临床观察  

Clinical observation of BP plus PF to malignant tumors in middl and late periods

作　　者：张清琴[1] 牛红蕊[1] 

机构地区：[1]新乡医学院第一附属医院肿瘤科,河南卫辉453100

出　　处：《医学信息（内.外科版）》2009年第1期46-47,51,共3页Medical Information Operations Sciences Fascicule

摘　　要：目的观察BP素对中晚期恶性肿瘤辅助疗效。方法将90例中晚期肿瘤病人随机分为两组:BP素组:PF加BP素组;对照组:单用PF组。治疗前后对患者外周白细胞、红细胞、血色素、血小板、食欲、消化道反应、疼痛、体重、Karnofsky评分、疗效进行评价。结果BP素组白细胞减少程度及疗效均好于对照组,临床症状及生活质量,BP素组显著改善,两组比较有显著差异(P<0.05),免疫指标CD3、CD4、CD4/CD8、NK活性显著提高,两组比较有显著差异(P<0.05)。结论PF方案加BP素可以增加疗效、减轻骨髓毒性及消化道反应、提高机体免疫力、提高病人生存质量和化疗耐受性。Objective To observe possible auxiliary therapeutic effect of BP for advanced malignant tumors. Methods Ninty patients were randomly divided into two groups. One was BP group（PF plus BP）. Another was control group（only with PF）. The lukocyte ,red blood cell, haemoglobin and plateh, toxicity of digestive tract, pain response, body weight, and state of Karnofsky and effective rate of those patients were evaluated respectively before and after therapy. Results The clinical effect and downregulation of lukocyte were better in BP group than in control group. The quality of life and clinical symptom of the patients in BP were improved more obviously than those in control group （P 〈0.05 ,P 〈0.01 ）. The results of CD3 ,CD4, CD4/CD8 and NK were higher in BP group than that in control group. The difference was statistically significant（ P 〈 0.05 ）. Conclusions BP combined with PF can improve the therapeutic effect, reduce the toxicities of digestive tract and blood, enhance the immunity and quality of life, and increase tolrance of patients for chemotherapy.

关 键 词：BP素 恶性肿瘤 抗肿瘤联合化疗方案 

分 类 号：R614[医药卫生—麻醉学]